# US 2016/0355782 A1 · Method for enhancing differentiation of dopaminergic neurons

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355782 A1
- Document ID: US20160355782A1
- Status: Published application
- Kind: A1
- Application number: 14/732,889
- Filed: 2015-06-08
- Published: 2016-12-08
- Earliest claimed: 2015-06-08
- Assignees: Buddhist Tzu Chi Medical Foundation
- Applicants: Buddhist Tzu Chi Medical Foundation
- Inventors: Mei-Jen Wang; Hsin-Yi Huang; Tsung-Lang Chiu; Hui-Fen Chang; Hui-Ru Hsu; Cheng-Yoong Pang; Hock-Kean Liew
- Web page: https://patentgrep.com/patent/US20160355782A1

## CPC

- C12N 5/0619: {Neurons}
- C12N 2501/065: Modulators of histone acetylation
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2506/08: from cells of the nervous system
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method for enhancing differentiation of dopaminergic (DA) neurons is provided. The method of the present invention includes culturing precursor cells; administering urocortin to the precursor cells; and differentiating the precursor cells into the DA neurons.

## Claims

### Claim 1

A method for enhancing differentiation of dopaminergic (DA) neurons, comprising culturing precursor cells in a DMEM/F12/N2 medium; administering urocortin (UCN) to the precursor cells; and differentiating the precursor cells into the DA neurons.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the DA neurons are midbrain DA neurons.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the precursor cells are midbrain DA precursor cells, Nurr1-expressing neural precursor cells (NPCs), or DA neuro-blastoma.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the differentiation of DA neurons is late differentiation of DA precursor cells.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the UCN is administered at an amount of 0.25 μM to 1 μM.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the UCN is administered at an amount of 0.5 μM to 1 μM.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the UCN is administered at an amount of 1 μM.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the precursor cells are administered with the UCN for 1 to 8 days.

### Claim 9 (depends on 1)

The method of claim 1, further comprising measuring a level of at least one DA phenotype gene in the precursor cells.

### Claim 10 (depends on 9)

The method of claim 9, wherein the at least one of the DA phenotype gene is selected from the group consisting of tyrosine hydroxylase (TH), dopamine transporter (DAT), 1-aromatic amino acid decarboxylase (AADC) and vesicular monoamine transporter (VMAT2).

### Claim 11 (depends on 1)

The method of claim 1, further comprising determining an activity of histone deacetylase (HDAC) and measuring a level of acetylated histone H3 (Ac-H3) in the precursor cells.

### Claim 12 (depends on 1)

The method of claim 1, further comprising measuring a level of transcription factors Nurr1, Foxa2, and Pitx3 in the precursor cells.

### Claim 13

A method for producing midbrain dopaminergic (DA) neurons, comprising culturing midbrain DA precursor cells in a DMEM/F12/N2 medium; administering UCN to the midbrain DA precursor cells and differentiating the midbrain DA precursor cells into the midbrain DA neurons.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the UCN is administered at an amount of 0.25 μM to 1 μM.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the UCN is administered at an amount of 0.5 μM to 1 μM.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the UCN is administered at an amount of 1 μM.

### Claim 17 (depends on 13)

The method according to claim 13, wherein the midbrain DA precursor cells are administered with the UCN for 1 to 8 days.

### Claim 18 (depends on 13)

The method of claim 13, further comprising measuring a level of at least one DA phenotype gene in the midbrain DA precursor cells, wherein the at least one of the DA phenotype gene is selected from the group consisting of tyrosine hydroxylase (TH), dopamine transporter (DAT), 1-aromatic amino acid decarboxylase (AADC) and vesicular monoamine transporter (VMAT2).

### Claim 19 (depends on 13)

The method of claim 13, further comprising determining an activity of histone deacetylase (HDAC) and measuring a level of acetylated histone H3 (Ac-H3) in the midbrain DA precursor cells.

### Claim 20 (depends on 13)

The method of claim 13, further comprising measuring a level of the transcription factors Nurr1, Foxa2 and Pitx3 in the midbrain DA precursor cells.
